bpc 157 peptide fda This is the first vote from the FDA's Pharmacy Compounding Advisory Committee on one of 7 peptides up for consideration. While the committee advises through these votes, ultimately the will make FDA Just Changed the Future

In a phase 2 dose-finding trial, once-weekly Cagrilintide produced clinically meaningful weight loss about 10.8% at the 4.5 mg dose over 26 weeks with gastrointestinal effects the most common adverse events [1]

Lupus and Osteoporosis Compared with the general population, people with lupus are at an increased risk for osteoporosis, which is an accelerated loss of bone mass

This often includes patients with: Pernicious anemia, a condition where the body cannot absorb B12 due to a lack of intrinsic factor, a protein produced in the stomach

In simple terms, low B12 is a proven risk, high B12 is a theoretical one, and normal, doctorguided doses are usually safe for hair